Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
Mame Daro Faye(University of Ottawa), Bassam Abdulkarim(University of Alberta), Jacob C. Easaw(Alberta Health Services), Alexander Torres-Vasquez(McGill University Health Centre), Valérie Panet-Raymond(McGill University Health Centre), Siham Sabri(Applied Science Private University), J. E. Alkass(McGill University Health Centre), Scott Owen(McGill University Health Centre), Maryam Azam(McGill University Health Centre), Frederic Lamonde(McGill University Health Centre), Bushra Hossain(University of California, San Francisco), Raman Agnihotram(McGill University Health Centre), George Shenouda(McGill University Health Centre), Kevin Petrecca(McGill University Health Centre), Paula de Robles(Cancer Institute (WIA)), Luís Souhami(McGill University Health Centre)
Cited by 5
Related Papers
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05
|International Journal of Radiation Oncology*Biology*Physics|2000|1.6k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k